Loading patent…
AssigneeMedImmune, LLC
InventorsJAMES F. YOUNG, SCOTT KOENIG, LESLIE S. JOHNSON, WILLIAM D. HUSE, JEFFREY D. WATKINS, HERREN WU
Estimating the term…
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection
An antibody that immunospecifically binds to a respiratory syncytial virus (RSV) antigen, wherein the antibody comprises:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A fusion protein comprising a CDR having the amino acid sequence of a CDR listed in Table 2 or Table 3 and a heterologous amino acid sequence.
(canceled)
A method for preventing one or more symptoms of a RSV infection in a human subject, comprising administering to the subject a first dose of a prophylactically effective amount of an antibody that immunospecifically binds to a RSV antigen, wherein the prophylactically effective amount is a dose of less than 15 mg/kg of the antibody, and wherein the prophylactically effective amount of the antibody results in a prophylactically effective serum titer of at least 75 μg/ml at least 30 days after the administration of the first dose and to prior to the administration of a subsequent dose.
A method for treating or ameliorating one or more symptoms of a RSV infection in a human subject, comprising administering to the subject a first dose of a therapeutically effective amount of an antibody that immunospecifically binds to a RSV antigen, wherein the therapeutically effective amount is a dose of less than 15 mg/kg of the antibody, and wherein the therapeutically effective amount of the antibody results in a therapeutically effective serum titer of at least 75 μg/ml at least 30 days after the administration of the first dose and to prior to the administration of a subsequent dose.
Dependencies are inferred from the claim text.